In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Vertex Pharmaceuticals, with a price target of $460.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mohit Bansal’s rating is based on several factors impacting Vertex Pharmaceuticals. The recent data on VX-993 did not meet expectations, showing weaker results compared to VX-548. This suggests that Vertex might have already achieved the optimal dose response with VX-548, and further improvements may be challenging without new combinations.
Additionally, the company’s decision to not pursue a Phase 3 trial for a broader chronic pain label and instead focus on a narrower diabetic peripheral neuropathy (DPN) label could limit market opportunities. This shift in strategy may delay potential market entry by 2-3 years, affecting the company’s growth prospects in the chronic pain segment. Despite some positive sales figures for other products, these concerns contribute to the Hold rating.
In another report released on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $480.00 price target.